129 related articles for article (PubMed ID: 33481504)
1. Expression of TIGAR and its correlation with clinicopathology, prognosis, and 18F-FDG PET/CT parameters in patients with resectable pancreatic ductal adenocarcinoma.
Song Y; Wang PY; Zheng Y; Liu C; Wang XM
Nucl Med Commun; 2021 May; 42(5):528-534. PubMed ID: 33481504
[TBL] [Abstract][Full Text] [Related]
2. Usefulness of FDG PET/CT derived parameters in prediction of histopathological finding during the surgery in patients with pancreatic adenocarcinoma.
Myssayev A; Myssayev A; Ideguchi R; Eguchi S; Adachi T; Sumida Y; Tobinaga S; Uetani M; Kudo T
PLoS One; 2019; 14(1):e0210178. PubMed ID: 30629646
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of 18F-FDG PET/CT parameters for reflection of aggressiveness and prediction of prognosis in early-stage cervical cancer.
Zhang L; Sun H; Du S; Xu W; Xin J; Guo Q
Nucl Med Commun; 2018 Nov; 39(11):1045-1052. PubMed ID: 30204642
[TBL] [Abstract][Full Text] [Related]
4. Associations of volumetric whole-body
Araç E; Can C; Kömek H
Hell J Nucl Med; 2020; 23(1):40-47. PubMed ID: 32361716
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Value of Metabolic Tumor Volume and Total Lesion Glycolysis on Preoperative ¹⁸F-FDG PET/CT in Patients with Pancreatic Cancer.
Lee JW; Kang CM; Choi HJ; Lee WJ; Song SY; Lee JH; Lee JD
J Nucl Med; 2014 Jun; 55(6):898-904. PubMed ID: 24711649
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Value of Metabolic and Volumetric Parameters of Preoperative FDG-PET/CT in Patients With Resectable Pancreatic Cancer.
Im HJ; Oo S; Jung W; Jang JY; Kim SW; Cheon GJ; Kang KW; Chung JK; Kim EE; Lee DS
Medicine (Baltimore); 2016 May; 95(19):e3686. PubMed ID: 27175707
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of volume-based 18F-FDG PET/CT parameters and correlation with PD-L1 expression in patients with surgically resected lung adenocarcinoma.
Wang D; Li Y; Chen X; Li P
Medicine (Baltimore); 2021 Sep; 100(35):e27100. PubMed ID: 34477147
[TBL] [Abstract][Full Text] [Related]
8. FDG PET/CT metabolic tumor volume and total lesion glycolysis predict prognosis in patients with advanced lung adenocarcinoma.
Chung HW; Lee KY; Kim HJ; Kim WS; So Y
J Cancer Res Clin Oncol; 2014 Jan; 140(1):89-98. PubMed ID: 24194352
[TBL] [Abstract][Full Text] [Related]
9. The correlation of
Qu YH; Long N; Ran C; Sun J
Clin Transl Oncol; 2021 Mar; 23(3):620-627. PubMed ID: 32683540
[TBL] [Abstract][Full Text] [Related]
10. Volumetric parameters of 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography/computed tomography can predict histopathologic treatment response after neoadjuvant chemoradiotherapy in pancreatic adenocarcinoma.
Sakane M; Tatsumi M; Hori M; Onishi H; Tsuboyama T; Nakamoto A; Ota T; Eguchi H; Wakasa K; Hatazawa J; Tomiyama N
Eur J Radiol; 2017 Sep; 94():64-69. PubMed ID: 28712692
[TBL] [Abstract][Full Text] [Related]
11. Prediction of tumour grade and survival outcome using pre-treatment PET- and MRI-derived imaging features in patients with resectable pancreatic ductal adenocarcinoma.
Dunet V; Halkic N; Sempoux C; Demartines N; Montemurro M; Prior JO; Schmidt S
Eur Radiol; 2021 Feb; 31(2):992-1001. PubMed ID: 32851447
[TBL] [Abstract][Full Text] [Related]
12. Correlation study on 18F-FDG PET/CT metabolic characteristics of primary lesion with clinical stage in lung cancer.
Hu WD; Wang HC; Wang YB; Cui LL; Chen XH
Q J Nucl Med Mol Imaging; 2021 Jun; 65(2):172-177. PubMed ID: 30916535
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Value of Pretreatment Metabolic Tumor Volume and Total Lesion Glycolysis Using 18F-FDG PET/CT in Patients With Metastatic Renal Cell Carcinoma Treated With Anti-Vascular Endothelial Growth Factor-Targeted Agents.
Hwang SH; Cho A; Yun M; Choi YD; Rha SY; Kang WJ
Clin Nucl Med; 2017 May; 42(5):e235-e241. PubMed ID: 28288043
[TBL] [Abstract][Full Text] [Related]
14. Usefulness of
Yokose T; Kitago M; Matsusaka Y; Masugi Y; Shinoda M; Yagi H; Abe Y; Oshima G; Hori S; Endo Y; Toyama K; Iwabuchi Y; Takemura R; Ishii R; Nakahara T; Okuda S; Jinzaki M; Kitagawa Y
Cancer Med; 2020 Jun; 9(12):4059-4068. PubMed ID: 32281301
[TBL] [Abstract][Full Text] [Related]
15.
Satoh K; Sadowski SM; Dieckmann W; Quezado M; Nilubol N; Kebebew E; Patel D
Ann Surg Oncol; 2016 Dec; 23(Suppl 5):714-721. PubMed ID: 27638678
[TBL] [Abstract][Full Text] [Related]
16. Volume-based parameters on FDG PET may predict the proliferative potential of soft-tissue sarcomas.
Kitao T; Shiga T; Hirata K; Sekizawa M; Takei T; Yamashiro K; Tamaki N
Ann Nucl Med; 2019 Jan; 33(1):22-31. PubMed ID: 30196378
[TBL] [Abstract][Full Text] [Related]
17. The Significance of FDG PET/CT-Derived Parameters in Determining Prognosis of Cases with Pancreatic Adenocarcinoma: A Prospective Study.
Mokhtar HM; Youssef A; Naguib TM; Magdy AA; Salama SA; Kabel AM; Sabry NM
Medicina (Kaunas); 2022 Aug; 58(8):. PubMed ID: 36013494
[TBL] [Abstract][Full Text] [Related]
18. Roles of metabolic tumor volume and total lesion glycolysis on 18F-FDG PET/CT, CA19-9 levels, and complete blood count parameters in predicting survival in patients with unresectable or metastatic pancreatic cancer.
Erdur E; Guzel Y; Yildirim OA; Poyraz K; Yildirim MS; Kaplan H
Ann Ital Chir; 2022; 93():85-95. PubMed ID: 35166229
[TBL] [Abstract][Full Text] [Related]
19. Metabolic Tumor Burden Assessed by Dual Time Point [
Garcia-Vicente AM; Pérez-Beteta J; Pérez-García VM; Molina D; Jiménez-Londoño GA; Soriano-Castrejón A; Martínez-González A
Mol Imaging Biol; 2017 Aug; 19(4):636-644. PubMed ID: 27981471
[TBL] [Abstract][Full Text] [Related]
20. Volumetric parameters on
Liu G; Hu Y; Cheng X; Wang Y; Gu Y; Liu T; Shi H
BMC Cancer; 2019 Aug; 19(1):790. PubMed ID: 31395059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
